Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | CASR | P41180 | 1/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.34 |
| ▸ | GLS | O94925 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL660878 | 1.00 | AGXT (0.42) | AGXTCYP2A6ADRB2ASIC3LOXL2 | |
| SCHEMBL6844411 | 1.00 | AGXT (0.42) | AGXTCYP2A6ADRB2ASIC3LOXL2 | |
| SCHEMBL4415054 | 0.88 | AGXT (0.40) | AGXTCYP2A6ADRB2ASIC3LOXL2 | |
| SCHEMBL4415050 | 0.88 | AGXT (0.40) | AGXTCYP2A6ADRB2ASIC3LOXL2 | |
| SCHEMBL15200886 | 0.79 | CYP2A6 (0.37) | AGXTCYP2A6ADRB2ASIC3LOXL2 | |
| SCHEMBL15200887 | 0.79 | CYP2A6 (0.37) | AGXTCYP2A6ADRB2ASIC3LOXL2 | |
| SCHEMBL660877 | 0.78 | CYP2A6 (0.36) | AGXTCYP2A6ADRB2ASIC3LOXL2 | |
| SCHEMBL18022045 | 0.78 | ALOX5 (0.37) | AGXT | |
| SCHEMBL662224 | 0.78 | AGXT (0.43) | AGXTCYP2A6ADRB2ASIC3LOXL2 | |
| SCHEMBL970714 | 0.78 | HTR2A (0.41) | CYP2A6CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637467-B2 | Treatment of inflammatory bowel disease | ALLERGAN, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9334262-B2 | Methods of treating soft tissue defects | ALLERGAN, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20160096817-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALLERGAN, INC. | 2016-04-07 | — | — | US | disclosed |
| US-9005605-B2 | Compositions and soft tissue replacement methods | ALLERGAN, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-8926963-B2 | Compositions and soft tissue replacement methods | ALLERGAN, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8900571-B2 | Compositions and soft tissue replacement methods | ALLERGAN, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8894992-B2 | Compositions and soft tissue replacement methods | ALLERGAN, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8889123-B2 | Compositions and soft tissue replacement methods | ALLERGAN, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8883139-B2 | Compositions and soft tissue replacement methods | ALLERGAN INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20140179752-A1 | METHODS OF TREATING SOFT TISSUE DEFECTS | ALLERGAN, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20120045420-A1 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS | ALLERGAN, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2012024072-A1 | COMPOSITIONS COMPRISING ADIPOSE TISSUE AND A PGE2 ANALOGUE AND THEIR USE IN THE TREATMENT OF A SOFT TISSUE CONDITION | ALLERGAN, INC. (US) | 2012-02-23 | — | — | WO | disclosed |
| US-20110172435-A1 | Treatment Of Inflammatory Bowel Disease | ALLERGAN, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| EP-1812387-B1 | 2,3,4-SUBSTITUTED CYCLOPENTANONES AS THERAPEUTIC AGENTS | ALLERGAN INC (US) | 2011-01-05 | — | — | EP | disclosed |
| US-7855226-B2 | Treating inflammatory bowel disease by administering prostaglandin derivatives such as (3-{(1R,4S,5S)-5-(3-chloro-benzo[b]thiophen-2-yl)-3-hydroxy-pent-1-enyl]-4-hydroxy-3,3-dimethyl-2-oxo-cyclopentylsulfanyl}-propylsulfanyl)-acetic acid methyl ester | ALLERGAN, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| EP-1812387-A1 | 2,3,4-SUBSTITUTED CYCLOPENTANONES AS THERAPEUTIC AGENTS | Allergan, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| US-7101906-B2 | 2,3,4-substituted cyclopentanones as therapeutic agents | ALLERGAN, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| WO-2006055481-A1 | 2,3,4-SUBSTITUTED CYCLOPENTANONES AS THERAPEUTIC AGENTS | ALLERGAN , INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| US-20060106088-A1 | 2,3,4-Substituted cyclopentanones as therapeutic agents | ALLERGAN, INC. (US) | 2006-05-18 | — | — | US | disclosed |
| US-20050164992-A1 | Treating inflammatory bowel disease by administering prostaglandin derivatives such as (3-{(1R,4S,5S)-5-(3-chloro-benzo[b]thiophen-2-yl)-3-hydroxy-pent-1-enyl]-4-hydroxy-3,3-dimethyl-2-oxo-cyclopentylsulfanyl}-propylsulfanyl)-acetic acid methyl ester | ALLERGAN, INC. (US) | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179752-A1 | METHODS OF TREATING SOFT TISSUE DEFECTS | TNNC1, COL2A1, ALPP | AGXT 565/4885CYP2A6 4064/4885ADRB2 4794/4885 |
| US-20160096817-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | SLC10A2, FABP2, LTB4R2 | AGXT 999/4885CYP2A6 1608/4885ADRB2 639/4885 |
| US-20050164992-A1 | Treating inflammatory bowel disease by administering prostaglandin derivatives such as (3-{(1R,4S,5S)-5-(3-chloro-benzo[b]thiophen-2-yl)-3-hydroxy-pent-1-enyl]-4-hydroxy-3,3-dimethyl-2-oxo-cyclopentylsulfanyl}-propylsulfanyl)-acetic acid methyl ester | PTGER1, PTGES, PTGS1 | AGXT 958/4885CYP2A6 442/4885ADRB2 315/4885 |
| US-20060106088-A1 | 2,3,4-Substituted cyclopentanones as therapeutic agents | CYCS, CA6, COX6C | AGXT 1981/4885CYP2A6 11/4885ADRB2 2452/4885 |
| US-20110172435-A1 | Treatment Of Inflammatory Bowel Disease | SLC10A2, FABP2, LTB4R2 | AGXT 999/4885CYP2A6 1608/4885ADRB2 639/4885 |
| US-20120045420-A1 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS | COL2A1, MATR3, TNNC1 | AGXT 261/4885CYP2A6 2985/4885ADRB2 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.